title: [Epidemiological study of hepatitis A and E viruses in different populations in Uruguay].
abstract: The hepatitis A and E virus (HAV and HEV) share the fecal-oral mechanism. Hepatitis A is an endemo-epidemic disease in Uruguay but no data on the epidemiologic pattern of the HEV is available. The aims of this study were to update the epidemiologic behavior of the HAV in Montevideo and demonstrate the circulation of the HEV in Uruguay. Two hundred fourteen patients who consulted in the Policlínica de Nutrición y Digestivo were studied, 185 (86%) of whom were anti HAV (HAVAB, Abbot) positive. 81.8% (117/143) of those residents in Montevideo and 95.7% (68/71) of those who were from the inland were anti-HAV positive. From the Montevideo population 55.8% cases under the age of 40 years were anti-HAV positive and occurred in 97.6% of those older (p < 0.001). Considering the health care conditions of the positive patients in Montevideo, 95.6% (43/45) had septic chambers and 75.5% (74/98) disposed of toilet facilities (p < 0.001). It is concluded that although the global prevalence has been maintained since 1982, there is a change in the epidemiologic pattern with greater risk of infection in patients under the age of 40 years proceeding from areas without toilet facilities. The prevalence of total antibodies for HEV (EIA, Abbot) was 2.8% in this population. An association was observed with HAV in 2.2% (4/185). Moreover, a sample of 252 blood donors from the National Blood Service was analyzed with 5 being found to be anti HEV positive, with only 3 (1.2%) being confirmed in the Center for Disease Control in the United States. Although no definitive conclusions may be drawn from the present study, from an epidemiologic point of view, it has been shown that there is evidence of the circulation of HEV in Uruguay, in both the out patient and in blood donor populations.
authors.affiliation: Clinica de Nutrición y Digestivo, Hospital de Clinicas, Montevideo, Uruguay.
authors.forename: M R
authors.initials: MR
authors.lastname: Cruells
authors.forename: G
authors.initials: G
authors.lastname: Mescia
authors.forename: R
authors.initials: R
authors.lastname: Gaibisso
authors.forename: M
authors.initials: M
authors.lastname: Ramírez
authors.forename: M
authors.initials: M
authors.lastname: Gutiérrez
authors.forename: S
authors.initials: S
authors.lastname: Kohen
authors.forename: M
authors.initials: M
authors.lastname: González
authors.forename: J
authors.initials: J
authors.lastname: Russi
authors.forename: H
authors.initials: H
authors.lastname: Chiparelli
authors.forename: L
authors.initials: L
authors.lastname: Ucar
authors.forename: M T
authors.initials: MT
authors.lastname: Pérez
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D005260:Female; D006506:Hepatitis A / Q000453:epidemiology*; D035922:Hepatitis A Antibodies; D006508:Hepatitis Antibodies / Q000032:analysis; D016751:Hepatitis E / Q000453:epidemiology*; D016752:Hepatitis E virus / Q000276:immunology; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012737:Sex Factors; D014583:Uruguay / Q000453:epidemiology
chemical_list: D035922:Hepatitis A Antibodies; D006508:Hepatitis Antibodies